Alectinib, a selective anaplastic lymphoma kinase (ALK) TKI that lacks interaction with c-Met, has high activity in ALK mutant NSCLC patients; alcetinib treatment in ALK positive patients was associated with increased median progression free survival and high response rate [88]. The gene discussed is MET; the disease is non-small cell lung carcinoma.